Linked e-resources

Details

Part I: Overview of the latest recommendations of the European Germ Cell Cancer Group
Part II: Special topics about controversial aspects, new results from studies, which might change treatment recommendations and long-term-survivorship: Is there still an indication for radiotherapy in seminoma CS I/ IIA/B?- How should we treat nonseminoma CSI?
Is there still an indication for diagnostic RPLND in nonseminoma CSI?
How could the prognosis of patients with intermediate risk disease be improved?
How should patients with poor-prognosis disease be treated actually?
How should patients with recurrent disease be treated actually?
How important are prognostic factors for determining treatment in patients with primary or recurrent disease?
What should be the boundaries in retroperitoneal residual tumor resection in nonseminoma?
How should residual disease outside the retroperitoneum be treated?
What are the recent recommendations for follow up in testicular cancer?
What are the long-term toxicities to be controlled and treated?
Consequences of the disease and its treatment concerning sexuality and fertility.

Browse Subjects

Show more subjects...

Statistics

from
to
Export